Fig. 4.
F-SLOH alleviates APP processing in AD mouse models. (A) F-SLOH treatment (10 and 20 mg/kg) reduces the protein expression levels of FL-APP and CTFs in the brain lysates of 5XFAD mice shown in immunoblot (B) and its corresponding quantification. (C) Chronic F-SLOH treatment reduced the protein expression levels of FL-APP and CTFs in the brain lysates of 3XTg-AD mice independent of BACE1, presenilin inhibition are shown in immunoblot and (D) its corresponding quantification. Quantified data presented as mean ± SEM. N = 8. (E) The cell viability test of F-SLOH on N2a cells overexpressing APP695 (N2a-APP) was determined using the MTT and its corresponding quantification. (F) F-SLOH treatment (6.25, 12.5, 25 and 50 μM) reduced the Aβ1-40 and Aβ1-42 protein expression levels in the cell media and its corresponding quantification. Each data represents the average of three replicates. (G) F-SLOH treatment (6.25, 12.5 and 25 μM) in N2a-APP cells significantly reduced the protein expression levels of FL-APP and CTFs and its representative blots are shown with its corresponding quantification. (H) F-SLOH mediated reduction of full-length APP were significantly blocked after BafA1 treatment at the indicated timepoint of CHX treatment in N2a-APP cells and its representative blots are shown with its (I) corresponding quantification. Each data represents the average of three replicates and data represented as mean ± SEM.